Internal Medicine

Medical Oncology

  • Professor: Hirotoshi Akita
  • Associate Professor: Ichiro Kinoshita
  • Assistant Professor: Satoshi Takeuchi
  • Assistant Professor: Rio Honma*
  • Assistant Professor: Yoshihito Ohhara
  • Phone: +81-11-706-5021
  • FAX: +81-11-706-5077
  • *concurrent
Department of Medical Oncology was established in 2001. Cancer is a major disease and cause of human death all over the world. We aim to cultivate medical oncologists who acquire well-rounded knowledge and skills on world-standard chemotherapy, multidisciplinary treatment of cancer, clinical trials and cancer-related symptom control. We are pursuing research to develop diagnostic and therapeutic methods in oncology by translating basic science into clinical medicine.


Basic cancer research has produced a wealth of knowledge during past few decades. Translational research promises to link biological understanding to patient care by translating biological understanding into therapeutic and diagnostic development. The aim of our research is to understand molecular pathophysiology of cancer, and to translate genetic and molecular information of cancer into clinical science, including search for molecular targets of cancer treatment as well as search and development of biomarkers for diagnosis, drug selection, drug-response prediction and prognosis of cancer.
1) Growth inhibition of non-small cell lung cancers by AP-1 blockade using a cJun dominant-negative mutant
2) Transformation of human bronchial epithelial cells and gene expression
3) Clinicopathological significance of expression of p-cJun, TCF4, and beta-Catenin in colorectal tumors
4) Key enzymes in the formation of asparagines-linked oligosaccharides in lung and GI cancers
5) E1AF/PEA3 activation of the Rho/ROCK pathway to increase the malignant potential of lung cancers
6) Genetic alteration of the EGFR gene and EGFR-TKI sensitivity in various types of cancer
7) Clinical trials of cancer chemotherapy in lung cancers (in cooperation with the First Department of Medicine) and GI cancers (in cooperation with the Third Department of Medicine)


Faculty members in this section give classes of Integrated Oncology I (basic oncology), Integrated oncology II (clinical oncology) and Clinical Practise (medical oncology) for medical students. We also take part in the courses of Medical Oncology for graduate students, covering researches on 1) diagnosis and treatment of malignant tumors, 2) molecular pathophysiology, diagnosis and treatment of lung cancers and mediastinal tumors, 3) molecular pathophysiology, diagnosis and treatment of tumors of the digestive organs, 4) cancer chemotherapy, 5) molecular targeting therapy of cancer, 6) molecular biological diagnosis and gene therapy of cancer. All these classes are given in Japanese.

International Activities

Recent Talks in International Conferences
1. Takeda K, et al. 98th Annual Meeting of the American Association for Cancer Research, Los Angeles, 2007.
2. Kikuchi J, et al. 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2006.
3. Shimizu Y, et al. 11th World Conference on Lung Cancer, Barcelona, Spain, 2005.
4. Shimizu Y, et al. 95th Annual Meeting of the American Association for Cancer Research, Orlando, 2004.
5. Ishibashi Y, et al. 95th Annual Meeting of the American Association for Cancer Research, Orlando, 2004.
6. Hakuma N, et al. 94th Annual Meeting of the American Association for Cancer Research, Washington, DC, 2003.

Ongoing International Collaborations
We have been collaborating with Dr. Michael J. Birrer of National Cancer Institute (USA) on the cJun/AP-1 project since 2001.
1 TAM67, a cJun dominant negative mutant, has most of the transactivation domain deleted. cJun is a major constituent of AP-1 transcription factor transducing multiple mitogen growth signals.
2 The colony-forming efficiency of non-small cell lung cancer cell lines, NCI-H1299 and A549, was reduced by TAM67.
3 TAM67 reduced growth of established xenograft tumors from the NCI-H1299 Tet-on clone cells in nude mice.
4 Members of Department of Medical Oncology in August, 2008.
Fig1 Fig2 Fig3 Fig4

Selected Publications

1. Shimizu Y, Kinoshita I, Kikuchi J, Yamazaki K, Nishimura M, Birrer MJ, Dosaka-Akita H. Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant. Br J Cancer. 98:915-22, 2008.
2. Hakuma N, Betsuyaku T, Kinoshita I, Itoh T, Kaga K, Kondo S, Nishimura M, Dosaka-Akita H. High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters. Oncology. 72:197-204, 2007.
3. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer, 95:998-1004, 2006.
4. Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, Dosaka-Akita H. E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell-lung cancer cells. Cancer Res., 65:10776-10782, 2005.
5. Ishibashi Y, Dosaka-Akita H, Miyoshi E, Shindoh M, Miyamoto M, Kinoshita I, Miyazaki H, Itoh T, Kondo S, Nishimura M, Taniguchi N. Expression of N-acetylglucosaminyltransferase V in the development of human esophageal cancers: immunohistochemical data from carcinomas and nearby noncancerous lesions. Oncology, 69:301-310, 2005.
6. Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katho H, Taniguchi N. Expression of N-Acetylglucosaminyltransferase V is associated with prognosis and histology in non-small cell lung cancers. Clin Cancer Res, 10:1773-1779, 2004.